Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
International Journal of Cardiology|April 12, 2005
Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS studyThao Huynh, Nicolo Piazza, Peter M DiBattiste, et al.
The American Journal of Cardiology|March 31, 2004
Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trialStephen J Servoss, Ying Wan, Steven M Snapinn, et al.
Clinical Therapeutics|June 18, 2003
An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension StudyKrister Kristianson, Frej Fyhrquist, Richard B Devereux, et al.
Diabetes Care|March 1, 2006
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE studyHans Ibsen, Michael H Olsen, Kristian Wachtell, et al.
Journal of the American Society of Nephrology : JASN|May 6, 2005
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang, Shahnaz Shahinfar, William F Keane, et al.
American Heart Journal|May 17, 2005
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trialJessica L Mega, David A Morrow, Marc S Sabatine, et al.
Kidney International|March 13, 2003
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Barry M Brenner, Dick de Zeeuw, et al.
Circulation|March 15, 2006
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension StudyPeter M Okin, Richard B Devereux, Eva Gerdts, et al.
The American Journal of Cardiology|November 29, 2005
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studiesAlbert A Carr, Peter R Kowey, Richard B Devereux, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Zhongxin Zhang, Paulette A Lyle, et al.
Pageof 3